SAREUM HOLDINGS PLC (SAR) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SAREUM HOLDINGS PLC Interim Results Investor Presentation. The company may not be in a position to answer every question it receives during the meeting itself. However, the company will review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to chairman, doctor Steven Parker. Good afternoon, sir. Hello. Good afternoon, everybody. Thank you for joining the call as we go through the half year results and the various pro progress that we made in the last few months to discuss. With that, I'm gonna hand you over to Tim Mitchell, our CEO, who will take you go through the presentation and and guide the q and a. Thank you. Thank you, Steven, and good morning, everybody. Thank you for joining us this afternoon. Sorry. Good afternoon. I'm here with our CSO, John Reeder. So John and I will take you through the results presentation, then we'll hand back to Alex who will host the q and a session. So so let me start with highlights from the past period. The main news for us, as we announced on Monday, is that we've applied to run the phase one clinical trial in Australia on SDC1801. That's our TYK2 JAK1 inhibitor for autoimmune diseases. So the preparatory work for this trial is all completed. We're expecting a decision on approval by the HREC, that's the human resource human, research ethics committee, and acceptance of the clinical trials notification by Australia's Therapeutic Goods Administration in the next few months. And we'll look to open this trial and start dosing healthy volunteers shortly after receiving this approval. So we'll go into more details on the study later on. But if we first look at the other programs...